Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Everolimus with RT/TMZ in First-line Glioblastoma
NCT00805961Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Jan 2009
- Primary completion
- Oct 2009
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and everolimus in glioblastoma multiforme (GBM), sponsored by SCRI Development Innovations. Primary endpoint: Progression-free Survival at 18 months. Started Jan 2009; status: completed.
02
Drugs
bevacizumabeverolimus
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00805961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00805961.